Market closed
Nkarta/$NKTX
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Nkarta
Nkarta Inc is a biopharmaceutical company engaged in developing engineered natural killer (NK) cells to treat cancer and autoimmune diseases. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer. The Company's operations are based in South San Francisco, California.
Ticker
$NKTX
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
159
Website
Nkarta Metrics
BasicAdvanced
$158M
-
-$1.79
0.87
-
Price and volume
Market cap
$158M
Beta
0.87
52-week high
$16.24
52-week low
$2.08
Average daily volume
1.4M
Financial strength
Current ratio
12.914
Quick ratio
12.709
Long term debt to equity
18.264
Total debt to equity
19.832
Management effectiveness
Return on assets (TTM)
-16.96%
Return on equity (TTM)
-30.40%
Valuation
Price to book
0.37
Price to tangible book (TTM)
0.37
Price to free cash flow (TTM)
-1.275
Growth
Earnings per share change (TTM)
-28.28%
3-year earnings per share growth (CAGR)
-10.20%
What the Analysts think about Nkarta
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Nkarta stock.
Nkarta Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Nkarta Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Nkarta News
AllArticlesVideos
Nkarta Announces IND Clearance of Investigator-Sponsored Trial in Myasthenia Gravis and Opening of Enrollment for Ntrust-2
GlobeNewsWire·2 months ago
Nkarta to Participate in an Upcoming Investor Conference
GlobeNewsWire·2 months ago
Nkarta to Participate in an Upcoming Investor Conference
GlobeNewsWire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Nkarta stock?
Nkarta (NKTX) has a market cap of $158M as of January 31, 2025.
What is the P/E ratio for Nkarta stock?
The price to earnings (P/E) ratio for Nkarta (NKTX) stock is 0 as of January 31, 2025.
Does Nkarta stock pay dividends?
No, Nkarta (NKTX) stock does not pay dividends to its shareholders as of January 31, 2025.
When is the next Nkarta dividend payment date?
Nkarta (NKTX) stock does not pay dividends to its shareholders.
What is the beta indicator for Nkarta?
Nkarta (NKTX) has a beta rating of 0.87. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.